PDCD1 across 12 cancers
PDCD1 is on the target list of 12 of the briefings. A drug aimed at it carries an FDA label naming the disease in 5, and is approved for some indication in 12. In the reference cohorts of the 12 with a mutation landscape it is altered in at least 5% of patients in 0 and in under 2% in 6 (Anal cancer, Cutaneous squamous cell carcinoma, Nasopharyngeal carcinoma, Head and neck cancer, Mesothelioma, Vulvar cancer) — a target there by expression, dependency or drug label, not by mutation.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials | Altered in the reference cohort |
|---|---|---|---|---|---|
| Anal cancer | approved here Retifanlimab | approved | 26 | 1 via PD-1 | 0.0% mut · 0.72% del n=139 |
| Basal cell carcinoma | approved here Cemiplimab | approved | 26 | 1 via PD-1 | 3.74% mut n=236 |
| Merkel cell carcinoma | approved here Retifanlimab | approved | 26 | 1 via PD-1 | 1.41% mut · 2.11% del n=142 |
| Cutaneous squamous cell carcinoma | approved here Cemiplimab | approved | 26 | 0 via PD-1 | 1.2% mut n=83 |
| Nasopharyngeal carcinoma | approved here Toripalimab | approved | 26 | 0 via PD-1 | 0.0% mut n=56 |
| Melanoma | approved elsewhere | approved | 26 | 10 via PD-1 | 3.65% mut · 1.91% del n=438 |
| Esophageal cancer | approved elsewhere | approved | 26 | 4 via PD-1 | 0.55% mut · 1.1% amp · 2.75% del n=182 |
| Head and neck cancer | approved elsewhere | approved | 26 | 4 via PD-1 | 0.39% mut · 0.39% amp · 1.55% del n=515 |
| Hodgkin lymphoma | approved elsewhere | approved | 26 | 3 via PD-1 | 3.28% mut n=61 |
| Cervical cancer | approved elsewhere | approved | 26 | 1 via PD-1 | 0.69% mut · 3.41% del n=291 |
| Mesothelioma | approved elsewhere | approved | 26 | 0 via PD-1 | 0.0% mut n=86 |
| Vulvar cancer | approved elsewhere | approved | 26 | 0 via PD-1 | 0.0% mut n=15 |
"Approved here" means a drug Open Targets records as aimed at PDCD1 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.